Biotechnologies

Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition

PR News Wire (Free subscription) | yesterday

CAMBRIDGE, Mass., Nov. 7, /PRNewswire/ -- Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school science competition....

Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity

PR News Wire (Free subscription) | yesterday

MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Early...

Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care

PR News Wire (Free subscription) | yesterday

MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients...

Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering

PR News Wire (Free subscription) | 11/06/2009

SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th

PR News Wire (Free subscription) | 11/06/2009

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product...

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

Life Science World (Free subscription) | 11/06/2009

[NEWS] LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ — BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. “We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously reco…...

GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update

Life Science World (Free subscription) | 11/06/2009

[NEWS] ATLANTA, Nov. 6 /PRNewswire-FirstCall/ — GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (“GeoVax” or “the Company”), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update....

Novavax Reports Third Quarter 2009 Financial Results

Life Science World (Free subscription) | 11/06/2009

[NEWS] ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones. Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share, for the same period...

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

PR News Wire (Free subscription) | 11/06/2009

LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

• BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results - Red Orbit
• BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results - Life Science World
• See the 4 articles on the same subject

Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009

Life Science World (Free subscription) | 11/06/2009

[NEWS] Achieves Record Quarterly Gross Margin of $92 Million WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ — Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the third quarter ended October 3, 2009. For the third quarter ended October 3, 2009, Par reported total revenues of $294.8 million an…

Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under ...

Life Science World (Free subscription) | 11/06/2009

[NEWS] - quarter-end cash of $13.4 million before milestone -<br /><br /> (all figures are in Canadian dollars unless otherwise noted)<br /> BELLEVILLE, ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting

PR News Wire (Free subscription) | 11/06/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November...

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

Life Science World (Free subscription) | 11/06/2009

[NEWS] Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss improves 86% year over year to ($0.2) million WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ — DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today...

EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus

PR News Wire (Free subscription) | 11/06/2009

VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.

Magnetic nanoparticles to simultaneously diagnose, monitor and treat

Life Science World (Free subscription) | 11/06/2009

[NEWS] Contact: Joe Winters joseph.winters@iop.org 44-020-747-04815 Institute of Physics Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as th…

Genentech, Inc. - Financial and Strategic Analysis Review

aarkstore | 09/14/2009

Genentech, Inc. - Financial and Strategic Analysis Review Summary : Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacturing, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Major focus of Genentech is on three areas namely; oncology, immunology, and tissue...

MedImmune, Inc. - Strategic Analysis Review

aarkstore | 09/12/2009

MedImmune, Inc. - Strategic Analysis Review Summary MedImmune, LLC.( MedImmune), a biotechnology company focused on the development, manufacture and commercialization of medicines for the indications in Infectious Diseases, Oncology, Inflammatory Disease, cardiovascular, gastrointestinal disease and neuroscience. Its marketed products include Synagis, Ethyol, FluMist and other products. It is headquartered...